Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
9.685 / 17.032
#77473

Re: Farmas USA

Esto... se les ha ido la pinza a los de la web Nasdaq, no?

NVAX's NASDAQ Last Sale (NLS) Volumen NLS Cierre anterior Alto / Bajo de hoy 52 semanas alto / bajo
7.57 0.11 ▼ 1.43% 715,802 $7.68 7.7999 / 6 $ 15.01 / $ 4.82

Mínimo intradía 6$? WTF???

#77479

Re: Farmas USA

Estais invitados todos los farmadictos que lleven valores con vacunas en sus pipeline (INO,NVAX, DVAX,etc,etc)
Se pueden enviar preguntas desde yá.
--
2015 PDA/FDA Vaccines Conference
The 2014 Ebola epidemic drew public attention to the challenges of developing effective vaccines. Conference Co-Chairs Bob Darius, Head, Vaccines Quality Advocacy Liaison, GSK Biologicals and Norman Baylor, PhD, President and CEO, Biologics Consulting Group, expand on the topics that will be covered at the 2015 PDA/FDA Vaccines Conference in this podcast.

Presented by PDA North America and PDA Europe, the 2015 PDA/FDA Vaccines Conference and concurrent 2015 PDA Joint Vaccines Conference will simulcast six presentations between two locations, Bethesda, MD, and Berlin, Germany. Participants in both locations will be able to hear these select presentations and take part in interactive question and answer sessions. Do you have questions or concerns that you’d like addressed by a panel of Government and Industry vaccine development experts? Submit your questions by Nov. 1 and hear answers to your most pressing questions at the 2015 PDA/FDA Vaccines Conference.
-
https://www.pda.org/global-event-calendar/event-detail/2015-pda-vaccines-conference?utm_source=FierceVaccines&utm_medium=Email&utm_campaign=VACFierceVaccines_Eblast_10.19.15&mkt_tok=3RkMMJWWfF9wsRonuKvPd%2B%2FhmjTEU5z14uUrWKS1lMI%2F0ER3fOvrPUfGjI4AScVrM6%2BTFAwTG5toziV8R7LMKM1ty9MQWxTk

Te puede interesar...
  1. Primeras dudas sobre la 'Trumponomics', ¿corrección o toma de beneficios?
  2. Huellas técnicas de largo plazo. ¿Salvará Nvidia al mercado?
  1. Inflación y tipos en el punto de mira, la historia no se repite pero rima
  2. La Euforia Post-Trump: ¿Calma o Tormenta en el Mercado?